LAUSR

Volume 66, no. 2, e01990-21, 2022, https://doi.org/10.1128/AAC.01990-21. Page 5, Table 1: The cefepime MIC50 for the A. baumannii complex, all isolates, should be 16mg/mL, and the % susceptible, % intermediate, and % resistant values for cefepime should be 43.3, 11.5, and 45.2, respectively. Page 5, Table 1: The cefepime MIC50 for the A. baumannii complex, meropenem-nonsusceptible, should be 64mg/mL, and the % susceptible, % intermediate, and % resistant values for cefepime should be 5.2, 15.7, and 79.1, respectively. Page 5, Table 1: The cefepime MIC90 for S. maltophilia, all isolates, should be#64mg/mL. Page 5, Table 1: The cefepime MIC50 for the B. cepacia complex, all isolates, should be 32mg/mL, and the cefepimeMIC50 for B. cepacia complex, meropenem-nonsusceptible, should be 64mg/mL. Page 5, Table 1: A footnote should be added to the table, stating, “Cefepime data from 2014 to 2018 only; A. baumannii complex (n = 4,184), A. baumannii complex meropenemnonsusceptible (n = 2,273), S. maltophilia (n = 1,564), B. cepacia complex (n = 265), and B. cepacia complex meropenem-nonsusceptible (n = 80)”. Page 10, Table 2: The 2019 cefepime data for the A. baumannii complex should be deleted, and the “Maximum difference in annual % susceptible from 2014 to 2019” values for cefepime should be 22.5 for North America and 21.4 for Europe. These changes do not change the conclusions of the paper.